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Patterns of Cardiac Perfusion Abnormalities After
Chemoradiotherapy in Patients with Lung Cancer
Isis W. Gayed, MD,* H. Helen Liu, PhD,† Xiong Wei, MD,† Zhongxing Liao, MD,‡
Syed Wamique Yusuf, MD,§ Joe Y. Chang, MD,‡ Roland Bassett, PhD, and Ritsuko Komaki, MD‡
Objective: We evaluated the prevalence of myocardial perfusion
defects using myocardial perfusion imaging (MPI) after chemora-
diation or radiation therapy (CRT/RT) in lung cancer patients and
described their patterns in relation to tumor location.
Methods: MPI in 44 patients who received RT for lung cancer and
44 control patients were compared. The two groups were compara-
ble in risk factors for coronary artery disease. Data regarding tumor
stage and location, interval between CRT/RT and MPI, and mean
radiation dose to the heart was collected. The level of radiation
delivered to the affected segments of the left ventricle versus the
normal segments was compared using the isodose lines on the
simulation computed tomography.
Results: Considering all tumor locations, 8 patients (18%) demon-
strated MPI defects after CRT/RT versus 9 (20%) in the controls.
However, 7 of 18 patients (39%) with centrally located tumors in the
CRT/RT group versus only 1 of 15 patients (7%) in the control
group demonstrated MPI defect (p 0.04). The defects in the
CRT/RT group were in the anterior and septal segments while the
defects were in different segments in the controls. The median
interval between end of RT and MPI was 12.3 months. The affected
segments in the CRT/RT group received a mean radiation dose of
39.6 versus 11.4 Gy (p  0.003) to the normal segments.
Conclusions: CRT/RT to centrally located lung tumors tends to
cause anterior/septal MPI defects. Abnormal MPI segments in the
CRT/RT group have received significantly higher radiation than
normal segments.
Key Words: Lung Cancer, Radiation therapy, Chemoradiation,
Myocardial perfusion imaging.
(J Thorac Oncol. 2009;4: 179–184)
Multiple studies in patients with lymphoma or left breastcancer have demonstrated detrimental effects of radio-
therapy (RT) on the heart.1–6 Researchers have studied the
effects of RT patients with these two particular types of
cancer to evaluate the effects of RT because of the longer
survival intervals after treatment which allowed for the long-
term side effects of RT to manifest. However, investigators
have demonstrated the early effects of RT using multiple
imaging modalities.7–9 For example, studies have found myo-
cardial perfusion abnormalities using myocardial perfusion
imaging (MPI) early after RT and even before the develop-
ment of clinical symptoms.10–14 The number of patients with
such perfusion abnormalities usually increases as the interval
after RT increases.15 Furthermore, echocardiography has
been used to assess the effects of radiation on the valves,
pericardium, and myocardial contractility.7,16 Both computed
tomography (CT) and echocardiography are useful in evalu-
ating the size and effects of pericardial effusions after RT.17
Thus, different noninvasive imaging modalities have
proven to be useful in early evaluation of the effects of RT
on the heart.
Improvements in cancer therapy have resulted in pro-
longed survival after initial diagnosis of many cancers that
were previously known to be lethal in short intervals. Addi-
tionally, screening and early detection of cancer have resulted
in early initiation of therapy. Presently, patients with cancer
tend to survive their disease long enough to experience the
long-term side effects of cancer therapy. Lung cancer is one
of the cancer types for which the 5-year survival rate has
improved over the past decade.18 Many patients diagnosed
with lung cancer receive chemoradiotherapy (CRT) early in
the course of their treatment. High-dose RT is usually deliv-
ered to the primary tumor and/or hilar lymph node metastases
in close proximity to the heart. This is anticipated to cause
myocardial perfusion abnormalities as seen using MPI. To
our knowledge, the effects of CRT or RT on myocardial
perfusion in patients with lung cancer have yet to be inves-
tigated adequately. There are no prior studies that described
the expected patterns of MPI abnormalities with CRT or RT
in patients with lung cancer. Therefore, in this study, we
investigated the prevalence of myocardial perfusion abnor-
malities in patients with lung cancer who received CRT/RT
and was compared with lung cancer patients who did not
receive CRT/RT before MPI. We also investigated the rela-
tionship between primary lung tumor location and the pat-
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terns of myocardial perfusion abnormalities in the patients
who received CRT/RT.
PATIENTS AND METHODS
Upon approval of our study by the Institutional Review
Board, a retrospective search of a prospectively collected
database in the nuclear medicine department of MPI studies
completed at our institution was performed. Data of 44
consecutive patients with lung cancer who underwent
CRT/RT before MPI from March 2003 to May 2006 were
extracted. The results of the MPI studies were compared with
those in a control group of 44 consecutive patients with lung
cancer who did not receive RT before MPI. The control group
patients were extracted from the same data base and their
MPI were performed between March to September of 2003.
The patients in the CRT/RT and control groups were com-
parable in their demographic characteristics and lung tumor
type. Patients for whom the interval between the end of
CRT/RT and the initiation of MPI was less than 2 months
were excluded since our previous experience demonstrated
that most RT related abnormalities are unlikely to develop in
such a short interval.19 The patients’ demographic data, tumor
histology, tumor stage, interval between CRT/RT and MPI,
RT technique, total radiation dose, mean radiation dose de-
livered to the heart were analyzed. Tumors medial to the mid
clavicular line were classified as central and lateral to the mid
clavicular line were classified as lateral in the lung. Tumors
extending on both sides of the mid clavicular line were
classified as both central and lateral in location. Most impor-
tantly, the locations of the primary lung tumors with or
without central lymph node metastasis and RT planning fields
were compared with the locations of myocardial perfusion
abnormalities seen in MPI studies. The level of radiation
delivered to the affected segments of the left ventricle (LV)
versus the normal segments was compared using the isodose
lines on the simulation CT for RT planning. The isodose line
is a contour identifying the boundary of a region within which
the dose is higher than the designated radiation dose level.
Isodose lines demonstrate the distribution of the RT dose in
3-dimensions which correlated well with the 3-dimensional
nature of MPI. Isodose lines containing the affected segments
in myocardial perfusion images as well as the rest of the LV
were recorded. Also, isodose lines encompassing the whole
LV in patients with normal myocardial perfusion were re-
corded. This correlation of isodose lines with abnormal ver-
sus normal myocardial perfusion segments was performed to
help identify the threshold RT dose above which ischemic
changes occurred.
Similar data were collected for the control group except
for the information related to CRT/RT since none of these
patients received RT.
MPI was performed as part of routine standard-of-care
studies for risk stratification before surgery in 43 patients,
multiple risk factors for coronary artery disease (CAD) in 24
patients, symptoms of chest pain or dyspnea in 19 patient, for
EKG abnormality in 1 patient and atrial fibrillation in another
patient. MPI was performed using a dual-isotope protocol
with 111 MBq (3 mCi) of thallium-201 injected intravenously
before the acquisition of a rest single-photon emission com-
puted tomography (SPECT) and 925–1110 MBq (25–30
mCi) of technetium-99m tetrofosmin injected at peak stress
30 minutes before a stress gated SPECT acquisition. Patients
were stressed using adenosine, dobutamine, and exercise in
57, 16, and 15 patients, respectively. The rest and stress
SPECT were acquired using a dual head gamma camera
(Philips-Cardio 60) over 180 degrees arc, 20 sec/frame, 64
frames in a 64  64 matrix using a low energy all purpose
collimator. The images were processed using filtered back
projection with a butterworth filter at the order of 5 and
frequency of 0.35 Nyquist. Gating was added to the stress
SPECT images in eight bins over the cardiac cycle. The
images are routinely interpreted by one out of five routine
readers and was reread by an additional expert reader who
was blinded to the locations of the lung tumors or the RT field
or dose. Difference between the routine reader and the expert
blinded reader was noted in only three patients in which the
expert reader interpretation was considered for the data anal-
ysis. Perfusion abnormalities were identified using a 13-
segment model of the LV. Perfusion abnormalities were
qualitatively graded as scar; mild, moderate, or marked isch-
emia; or mixed mild, moderate or marked ischemia with scar.
Functional information regarding left ventricular ejection
fraction, end-diastolic volume, and end-systolic volume was
also collected. The MPI findings for the CRT/RT group were
visually correlated with the different RT isodose lines as seen
on the simulation CT for RT planning used in these patients.
Statistical Analysis
Descriptive statistics were used to analyze the collected
data. The Wilcoxon test was used to analyze significant
differences in the continuous variables, such as in the func-
tional results of the MPI studies. The Fisher’s exact test was
used to analyze differences in risk factors for CAD and the 2
test to compare the prevalence of myocardial perfusion ab-
normalities between the two patient groups. p-values less
than 0.05 were considered statistically significant.
RESULTS
The demographics and lung cancer characteristics of
the patients in the CRT/RT and control groups are listed in
Table 1. Forty patients had CRT and four patients had RT
only in the CRT/RT group. In the control group, 24 patients
had chemotherapy. The two groups had similar distributions
of risk factors for CAD except for hypertension, which was
more prevalent in the control group than in the CRT/RT
group (Table 2).
The mean total radiation dose  SD (SD) delivered to
the lung tumor in the CRT/RT group was 56.6  9.6 Gy.
Thirty-five patients underwent three-dimensional (3D) con-
formal RT, and nine patients underwent intensity-modulated
RT (IMRT). The RT plans were available for review to obtain
the mean radiation dose delivered to the heart in 39 patients
in the CRT/RT group. The mean radiation dose  SD
delivered to the whole heart in this group was 18.3  10.3
Gy. The mean interval between the end of RT and the MPI
was 25.0  2.5 months (median, 12.3 months). We did not
observe a significant difference between the number of pa-
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tients with myocardial perfusion abnormalities in the
CRT/RT group and that in the control group (8 versus 9; p 
1.0) when all tumor locations were considered. However,
seven of the eight patients with MPI abnormality in the
CRT/RT group were in patients with centrally located tumors
and particularly of the left lung (Table 3). Additionally, 7 of
the 18 patients (39%) with centrally located lung cancer had
MPI abnormalities in the CRT/RT group while only 1 of the
15 patients (7%) with centrally located cancer had MPI defect
in the control group (p  0.046). In the CRT/RT group, four
patients had ischemia, two had scar, one had mixed scar and
ischemia in the same segments, and one had scar and isch-
emia in different segments of the LV. In the control group,
five patients had ischemia, two had scar, one had mixed scar
and ischemia in the same segments, and one had scar and
ischemia in different segments in the LV. Although the
numbers of abnormalities in the two groups were not signif-
icantly different, the pattern of LV defects was consistently
different. In the CRT/RT group, the anterior wall of the LV
was abnormal in five patients, the anteroseptal/septal wall
was abnormal in two patients, and the anteroseptal/apical
wall was abnormal in one patient. In the control group, the
abnormalities were distributed in almost all the different
segments of the LV as demonstrated in Figure 1.
Seven of the eight patients in the CRT/RT group who
had abnormal myocardial perfusion abnormalities received
3D conformal RT, whereas the remaining patient received
IMRT. When correlated with the RT plans, the affected LV
segments in the CRT/RT group received a mean radiation
dose of 39.6 Gy while the normal segments received a mean
radiation dose of 11.4 Gy (p  0.003). Figure 2 demonstrates
an example of a patient with left upper lung cancer and
FIGURE 1. The distribution of myocardial perfusion abnor-
malities in the left ventricular segments in patients in the
chemoradiation/radiation therapy (CRT/RT) and control
groups.
TABLE 3. Lung Cancer Tumor Location in the Patients with
Abnormal versus Normal MPIs Who Received RT
Abnormal MPIa Normal MPI
Central Both Central Lateral Both
R apex — — — — 6
RUL 1 1 4 1 2
RML — — 1 — —
RLL 1 — — 1 4
L apex — — — — 4
LUL 3 — 4 5 —
LLL 1 — 1 3 —
R main bronchus 1 — — — —
a None of the patients with abnormal MPI studies had a laterally located lung
cancer.
R, right; RUL, right upper lobe, RML, right middle lobe; RLL, right lower lobe; L,
left; LUL, left upper lobe; LLL, Left lower lobe; MPI, myocardial perfusion imaging;
RT, radiation therapy.
TABLE 1. Comparison of the Demographics of Lung
Cancer Patients Who Were Treated with CRT/RT versus the
Control Group
CRT/RT Group
(n  44)
Control Group
(n  44)
Age (yr) 65.8  9.4 69.0  5.2
Sex (F:M) 22:22 20:24
Tumor type
NSCLC 40 41
SCLC 4 3
Stage
I 7 17a
II 0 5a
III a 14 12
III b 13 5
IV 8 6
Recurrence 2 0
Location
LUL 12 14
LLL 5 5a
L hilum 4 1
RUL 15 6a
RML 1 1
RLL 6 16
R hilum 1 2
a One patient had two primary lung cancers.
NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; LUL, left upper
lobe; LLL, Left lower lobe; L, left; RUL, right upper lobe, RML, right middle lobe;
RLL, right lower lobe; R, right; F, female; M, male.
TABLE 2. Prevalence of Risk Factors for CAD in the CRT/RT
Group and the Control Group
Risk Factors for CAD
CRT/RT
Group
Control
Group p
Diabetes mellitus 7 9 0.79
Hypertension 20 31 0.03
Smoking 43 36 0.11
Family history of CAD 28 30 0.82
Obesity 4 2 0.68
Dyslipidemia 19 14 0.38
CRT/RT, chemoradiation/radiation therapy; CAD, coronary artery disease.
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anterior wall ischemia of the LV. All of the normal LV
segments in the CRT group were encompassed by isodose
lines of 20 Gy. An exception was noted in one patient with
normal MPI in whom the whole heart was included evenly in
high isodose lines of 40 to 50 Gy.
The mean left ventricular ejection fraction, end-dia-
stolic volume, and end-systolic volume  SD were 60.9 
14.6%, 71.6  24.5 ml, and 30.2  18.8 ml, respectively, in
the CRT group and 64.8  11.14% (p  0.19), 77.5  33.2
ml (p  0.69), and 30.2  23.1 ml (p  0.54), respectively,
in the control group. We observed no statistically significant
differences in the functional data between the two groups.
DISCUSSION
Our study demonstrated that the prevalence of myocar-
dial perfusion abnormalities in the patients with lung cancer
who received CRT/RT, considering all tumor locations, is
comparable to a control group of patients who did not receive
RT (18% versus 20%, respectively). However, we noted
consistent differences in the locations of myocardial perfu-
sion abnormalities in the two groups, as patients who re-
ceived CRT/RT had abnormalities in the anterior, anterosep-
tal and septal walls of the LV, whereas patients who did not
receive RT had abnormalities in different walls of the LV.
Also, 39% of the patients with centrally located tumors had
MPI abnormality in the CRT/RT group versus 7% in the
control group. This was statistically significant difference
between the two groups in patients with centrally located
tumors. Particularly, most of these patients had centrally
located left lung cancer. This is probably due to the close
proximity of these tumors to the heart. Interestingly, the
patients who demonstrated anteroseptal and septal defects
were the three patients who had centrally located right or
right main bronchus lung cancer. This was probably related to
the fact that the right ventricle is not visualized using MPI
and that the septal and anteroseptal regions are the most
medial portions of the LV involved in the RT field in patients
with centrally located right lung tumors.
Our findings confirm a previously described increase in
the prevalence of myocardial perfusion abnormalities in the
inferior wall of the LV, in patients with distal esophageal
cancer who received concurrent CRT (54%) compared with
that in patients who did not receive CRT (16%).19 In both
patients with distal esophageal cancer and those with cen-
trally located lung cancer or hilar metastases, the proximity of
the tumor to the heart results in delivery of high radiation
doses to the heart. Marks et al.15 demonstrated that at 6, 12,
18, and 24 months after RT, 27%, 29%, 38%, and 42%,
respectively, of patients with breast cancer had myocardial
perfusion abnormalities. Our finding of 39% prevalence of
MPI abnormalities in patients with centrally located tumors at
a mean interval of follow-up after CRT/RT of 25 months
(median 12.3 months) also are comparable to Marks et al.
findings in breast cancer patients. The myocardial perfusion
defects were also found to be associated with higher inci-
dence of chest pain in breast cancer patients.20 Harris et al.21
have recently demonstrated an overall difference in mortality
from cardiac causes in left-sided versus right-sided breast
cancer patients using contemporary tangential beam tech-
niques. Authors have also documented similar rates of myo-
cardial perfusion abnormalities in patients with lymphoma
who received RT.8 The clinical implications of MPI defects
seen is lung cancer patients have not been previously
investigated and is the subject of ongoing research at our
institution.
The literature is inconsistent regarding the etiology of
myocardial perfusion abnormalities caused by RT. For exam-
ple, Brosius et al.22 documented proximal CAD in autopsy
FIGURE 2. Myocardial perfusion images demonstrating an-
terior wall ischemia (arrows) (A) in a patient with left upper
lung cancer who had 3D conformal radiation therapy as
planned using simulation computed tomography (B).
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specimens obtained from patients who received RT with
fields that included the heart. Additionally, Girinsky et al.23
observed a lower incidence of RT-related cardiac complica-
tions with shielding of the proximal coronary arteries during
RT planning. Also Veinot et al.24 have demonstrated peri-
cardial coronary arteries lesions after RT by autopsy.
Heidenreich et al.8 also described the presence of coronary
stenosis greater than 50% in 55% of patients with abnor-
mal MPI and history of mediastinal irradiation and less than
50% in 22% of them. In contrast, Gyenes et al.12 suggested
that these perfusion abnormalities are probably caused by
microvascular damage in the heart. An interesting case report
by Letsas et al.25 described a patient who experienced an
acute myocardial infarction in the setting of normal coronary
arteries 16 years after irradiation of the chest for the treatment
of Hodgkin disease. Additionally, a recent case report by
Hong et al.9 described a patient with lymphoma who had a
myocardial perfusion abnormality as detected using positron
emission tomography but normal coronary arteries on a
coronary CT angiogram. We have observed during this study
and our previous study of patients with esophageal cancer
sharp geometric demarcation between abnormal and normal
myocardium in relation to the higher radiation isodose lines
of 40 to 45 Gy. The myocardial perfusion defect pattern is
similar to what is usually seen in bone, lung and brain scans
in patients who undergo irradiation of these organs. This is
supportive of the microvascular component of the damage.
Thus, the etiology of myocardial defects is probably due to
combination of radiation damage to both the epicardial cor-
onary arteries and the microvasculature of the heart.
One patient in our study who received homogenous
high radiation dose to the heart had normal myocardial
perfusion. Since MPI demonstrates relative decreased perfu-
sion to different segments of the LV, diffuse vascular in-
volvement may not be apparent. This may be a limitation of
MPI studies in such patients who receive homogeneous high
radiation doses to the heart. This phenomenon would be
similar to the previously described false negative results in
patients with balanced three-vessel CAD.26,27 Thus, we feel
that the MPI results in this patient may have been a false-
negative result because of the balanced diffuse effect of RT
on the left ventricular vasculature. However, we do not have
a supporting evidence to prove this hypothesis.
Since all of the detected myocardial perfusion abnor-
malities occurred in patients with centrally located lung
tumors, vigilance in RT planning to spare the heart in such
patients is necessary, especially when using 3D conformal
RT. In our study, seven of eight patients in the CRT group
who had myocardial perfusion abnormalities after RT under-
went 3D conformal RT, whereas the eighth underwent IMRT.
This suggests that patients with centrally located lung tumors
may be better candidates for proton therapy, when available,
since it is expected to deliver more targeted RT to the tumor
with less damage to the surrounding normal organs.
One limitation of our study is the fact that it was
retrospective with possible inaccurate documentation of the
risk factors for CAD in both study groups. However, in all of
the cases, our anesthesia and cardiology department collect
the risk factors for CAD in a structured reporting format
which helps more inclusive reporting system and more con-
fidence in the data collected with less likelihood of omission
of risk factors. Another limitation is the lack of use of
attenuation correction for the MPI studies in our institution.
However, the difference in location of MPI defects between
the CRT/RT group and the control group is unlikely to be
related or explained by attenuation artifacts since the distri-
bution of males to females was comparable in the two study
groups. The few number of abnormal MPI studies in both
study groups may also represent a limitation in our study.
Further validation of our results with large number of patients
would add valuable information of the cardiac effects of CRT
in lung cancer patients.
In conclusion, an association between centrally located
lung cancers and anterior/septal MPI defects is demonstrated
in our study. The affected MPI segments had a significantly
higher radiation dose than normal segments in the CRT/RT
group.
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